Multiply Labs announced a pilot collaboration with Kyverna Therapeutics (NASDAQ: KYTX), a clinical-stage biopharmaceutical company developing cell therapies for autoimmune diseases.
Through this partnership, Kyverna will evaluate automated manufacturing of its cell therapy processes using Multiply Labs' robotic systems for KYV-102, which incorporates a patented fully human CD19 CAR-T and proprietary whole-blood rapid manufacturing approach.
"This collaboration presents a unique opportunity to combine our deep expertise in manufacturing automation with Kyverna's innovative work in cell therapy. Our goal is to reduce labor costs, increase manufacturing efficiency, and ultimately scale cell and gene therapies to reach more patients faster."
Fred Parietti, Ph.D., Co-Founder & CEO, Multiply Labs
Multiply Labs' robotic systems work with industry-standard cell therapy manufacturing instruments while minimizing process modifications needed for automation. The company recently published an industry-first study comparing robotic execution versus manual methods for critical manufacturing steps, demonstrating comparable accuracy and precision.
The collaboration will leverage Resonance, Multiply Labs' robotic auto-training pipeline that enables rapid process learning from video demonstrations, combining video auto-segmentation with automated trajectory extraction.